Histogenics (NASDAQ:HSGX) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Thursday.
A number of other research analysts have also recently weighed in on HSGX. HC Wainwright set a $4.00 target price on Histogenics and gave the company a “buy” rating in a report on Friday, May 11th. Zacks Investment Research upgraded Histogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th.
Histogenics stock traded down $0.08 during midday trading on Thursday, reaching $2.07. The stock had a trading volume of 120,500 shares, compared to its average volume of 112,164. Histogenics has a twelve month low of $2.18 and a twelve month high of $2.20. The stock has a market capitalization of $61.68 million, a P/E ratio of -2.11 and a beta of 1.69.
Histogenics (NASDAQ:HSGX) last issued its earnings results on Thursday, May 10th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.45). analysts predict that Histogenics will post -0.81 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the business. Deutsche Bank AG lifted its stake in shares of Histogenics by 71.1% during the fourth quarter. Deutsche Bank AG now owns 71,706 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 29,806 shares in the last quarter. Virtu Financial LLC lifted its stake in shares of Histogenics by 413.4% during the fourth quarter. Virtu Financial LLC now owns 63,563 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 51,182 shares in the last quarter. Bradley Foster & Sargent Inc. CT acquired a new position in shares of Histogenics during the first quarter worth about $199,000. Renaissance Technologies LLC lifted its stake in shares of Histogenics by 54.8% during the fourth quarter. Renaissance Technologies LLC now owns 242,500 shares of the biotechnology company’s stock worth $497,000 after purchasing an additional 85,800 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of Histogenics during the first quarter worth about $320,000. Institutional investors own 43.21% of the company’s stock.
Histogenics Company Profile
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.